Breaking News

Top Analyst Reports For UnitedHealth, Citigroup & Honeywell

By Zacks Investment ResearchStock MarketsJul 22, 2019 02:31AM ET
Top Analyst Reports For UnitedHealth, Citigroup & Honeywell
By Zacks Investment Research   |  Jul 22, 2019 02:31AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Monday, July 22, 2019

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), Citigroup (C) and Honeywell (HON). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

UnitedHealth’s shares have gained +2% in the past year, outperforming the Zacks Medical Insurance industry, which has increased +1.7% over the same period. UnitedHealth Group’s earnings surpassed expectations by 4%, and were up 15% year over year. The Zacks analyst thinks the company stands apart in the industry by virtue of healthcare services, technology and innovations offered by its unit Optum.

Numerous acquisitions made by the company have broadened its business profile and provide benefits of diversification. Its solid balance sheet and consistent cash flow generation has enabled investment in business which will drive long term growth. Also, capital management through dividend payments and share buybacks is another positive.

However, slowdown of growth in international operations and underperformance of the Medicaid business are some concerns. An increase in leverage and substantial interest burden raises financial risk.

(You can read the full research report on UnitedHealth here >>>).

Shares of Citigroup have outperformed the Zacks Major Regional Banks industry in the past six months (+14.3% vs. +3.3%). The Zacks analyst thinks the company has an impressive earnings surprise history, beating expectations in all the trailing four quarters.

The company’s second-quarter 2019 results reflected expense control and higher revenues driven by consumer banking. However, lower fixed income, investment banking and equity market revenues amid challenging trading environment are acting as drags on the stock. Citigroup’s restructuring and streamlining efforts, along with strategic investments in core business, bode well for the long term.

Also, the company’s declining costs base supports its bottom-line improvement. Steady capital-deployment activities of the company are also commendable. However, pending litigation issues might keep legal expenses elevated.

(You can read the full research report on Citigroup here >>>).

Honeywell’s shares have outperformed the Zacks Diversified Operations industry in the past three months, gaining +0.4% vs. a -3.4% decline. In second-quarter 2019, Honeywell's earnings grew 8.8% year over year and exceeded expectations by about 1%.

The Zacks analyst thinks strength in its commercial aerospace, warehouse and process automation’s businesses as well as solid demand for its commercial fire and security products will boost revenues in the quarters ahead. Stronger sales volumes, increased productivity and ongoing commercial effectiveness actions will improve near-term profitability.

For 2019, Honeywell raised earnings guidance from $7.90-$8.15 to $7.95-$8.15 per share. However, the stock looks overvalued compared to the industry for the past three-month period. Also, the company is experiencing softness in its productivity products business.

(You can read the full research report on Honeywell here >>>).

Other noteworthy reports we are featuring today include IBM (IBM), Union Pacific (UNP) and Amgen (AMGN).

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read
Featured Reports

Ongoing Business Transition to Cloud, High Debt Hurt IBM

Per the Zacks analyst, IBM is having a tough time, given the ongoing time-consuming transition to a cloud business model. Stiff competition from peers & high indebtedness is another concern.

Cost Cuts Aid Union Pacific (UNP) Amid Weak Freight Revenues

The Zacks analyst likes the company's efforts to check costs. Union Pacific's initiatives to reward its shareholders are encouraging too. However, the sluggish freight scenario is worrisome.

Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes

While Amgen's newer drugs - Prolia, Xgeva, Blincyto, - will drive sales, biosimilar and brand competition for its legacy products should hurt the top line in 2019, per the Zacks analyst.

Production Expansion Aids Nucor (NYSE:NUE), Lower Prices A Woe

Per the Zacks analyst, Nucor should gain from efforts to expand production capacity and grow through acquisitions.

Seattle Genetics' (SGEN) Adcetris Advances Amid Competition

Per the Zacks analyst, Seattle Genetics aims to spur sales of its flagship product, Adcetris. The drug's label expansion studies raise hopes.

Higher Assets, Buyouts Aid Invesco (IVZ) Amid Cost Concerns

Per the Zacks analyst, Invesco's inorganic growth efforts, rise in assets under management and widening global presence will aid growth.

Loan Growth Aids Webster Financial (WBS), High Costs A Woe

Per the Zacks analyst, Webster Financial's organic strength is reflected by rising loans and deposits balances along with easing margin pressure.

New Upgrades

Danaher (NYSE:DHR) to Gain From Products, DBS Actions & Buyouts

Per the Zacks analyst, Danaher stands to gain from solid demand for products and effective implementation of Danaher Business System. Buyouts, including BioPharma business of GE, are another positive.

Growing Consumer Loans Aid Credit Acceptance's (CACC) Top Line

Per the Zacks analyst, increase in finance charges, driven by growth in consumer loans will likely aid Credit Acceptance's revenues. Its share repurchase plan reflects a solid balance sheet.

Skechers' (SKX) Robust International Business to Drive Sales

Per the Zacks analyst, Skechers' international business remains a key sales driver, apart from product innovation. International business is expected to rise in mid-teens over the balance of the year.

New Downgrades

Qualcomm (NASDAQ:QCOM) Marred by Stiff Competition & Waning Margins

Per the Zacks analyst, Qualcomm continues to face fierce competition from low-cost rival chipmakers like MediaTek, and leading smartphone makers like Samsung (KS:005930), which is hurting its operating margin.

High Costs & Debt Levels Plague J.B. Hunt (JBHT)

The Zacks analyst is concerned about J.B. Hunt's escalating operating expenses hampering its bottom-line growth. The company's high debt levels further add to its woes.

Higher Spending & Lower Production Volumes Ail Lear (LEA)

Per the Zacks analyst, decline in production volume in key markets and incremental spending on advanced engineering to support growth in electrification and connectivity are headwinds for Lear.

undefined undefined

Union Pacific Corporation (NYSE:UNP): Free Stock Analysis Report

UnitedHealth Group Incorporated (NYSE:UNH): Free Stock Analysis Report

International Business Machines Corporation (NYSE:IBM): Free Stock Analysis Report

Honeywell International Inc. (NYSE:HON): Free Stock Analysis Report

Citigroup Inc. (NYSE:C): Free Stock Analysis Report

Amgen Inc. (NASDAQ:AMGN): Free Stock Analysis Report

Original post

Zacks Investment Research
Top Analyst Reports For UnitedHealth, Citigroup & Honeywell
Top Analyst Reports For UnitedHealth, Citigroup & Honeywell

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email